SC-58125 is a selective cyclooxygenase 2 (COX-2) inhibitor with anti-inflammatory properties. SC-58125 blocks edema and hyperalgesia without causing gastric mucosal damage. SC-58125 also displays anti
tumor activity.
ChEBI: A member of the class of pyrazoles that is 1H-pyrazole substituted by a 4-fluorophenyl group at position 5, a 4-(methylsulfonyl)phenyl group at position 1 and a trifluoromethyl group at position 3. A selective cyclooxygenase 2 inhibitor
it exhibits anticancer property.
Selective cyclooxygenase 2 (COX-2) inhibitor (IC 50 values are 0.04 and >100 μ M for COX-2 and COX-1 respectively). Anti-inflammatory; blocks edema and hyperalgesia in vivo following an inflammatory insult, without causing gastric mucosal damage. Also displays antitumor activity.
SC-58125 (10 mg/kg; i.p. every 48 h) inhibits the growth of established colorectal cancer xenografts in mice[3].
SC-58125 (10 mg/kg; a single i.p.) reduces tumor PGE2 levels in mice[3].
SC-58125 (10 mg/kg; a single i.p.) does not change the tumor levels of COX-1 and COX-2 protein in mice[3].
| Animal Model: | Athymic Sprague-Dawley mice are injected HCA-7 cells[3] |
| Dosage: | 10 mg/kg |
| Administration: | I.p. every 48 h; at the time of tumor implantation or 2 and 4 weeks later |
| Result: | Decreased the tumor growth rates significantly. |
hCOX-2: 0.04 μM (IC50); hCOX-1: >100 μM (IC50)
![1-[(4-METHYLSULFONYL)PHENYL]-3-TRIFLUOROMETHYL-5-(4-FLUOROPHENYL)PYRAZOLE Structure](/CAS/GIF/162054-19-5.gif)
